Evidence map›Paper›PMID 21346736›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2011

Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers.

Andre F Marquand, Sara De Simoni, Owen G O'Daly, Steven C R Williams, Janaina Mourão-Miranda, Mitul A Mehta

Open access · hybridAbstract readClinical TrialComparative Study
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Assessing attention orienting in mice: a novel touchscreen adaptation of the Posner-style cueing task.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  14. Unravelling the effects of methylphenidate on the dopaminergic and noradrenergic functional circuits.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Andre F MarquandDepartment of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, King's College London, London, UK. andre.marquand@kcl.ac.uk
Sara De Simoni
Owen G O'Daly
Steven C R Williams
Janaina Mourão-Miranda
Mitul A Mehta
King's College London · GBWellcome Centre for Human Neuroimaging · GBUniversity College London · GB

Funding

Wellcome Trust 088641Wellcome Trust WT086565/Z/08/ZWellcome Trust WT088641/Z/09/Z
6 · The paper itself

Abstract

Stimulant and non-stimulant drugs can reduce symptoms of attention deficit/hyperactivity disorder (ADHD). The stimulant drug methylphenidate (MPH) and the non-stimulant drug atomoxetine (ATX) are both widely used for ADHD treatment, but their differential effects on human brain function remain unclear. We combined event-related fMRI with multivariate pattern recognition to characterize the effects of MPH and ATX in healthy volunteers performing a rewarded working memory (WM) task. The effects of MPH and ATX on WM were strongly dependent on their behavioral context. During non-rewarded trials, only MPH could be discriminated from placebo (PLC), with MPH producing a similar activation pattern to reward. During rewarded trials both drugs produced the opposite effect to reward, that is, attenuating WM networks and enhancing task-related deactivations (TRDs) in regions consistent with the default mode network (DMN). The drugs could be directly discriminated during the delay component of rewarded trials: MPH produced greater activity in WM networks and ATX produced greater activity in the DMN. Our data provide evidence that: (1) MPH and ATX have prominent effects during rewarded WM in task-activated and -deactivated networks; (2) during the delay component of rewarded trials, MPH and ATX have opposing effects on activated and deactivated networks: MPH enhances TRDs more than ATX, whereas ATX attenuates WM networks more than MPH; and (3) MPH mimics reward during encoding. Thus, interactions between drug effects and motivational state are crucial in defining the effects of MPH and ATX.

Indexed as

Adrenergic Uptake InhibitorsAdultAtomoxetine HydrochlorideCentral Nervous System StimulantsHumansMagnetic Resonance ImagingMaleMemory, Short-TermMethylphenidateNeuropsychological TestsPlacebo EffectPropylaminesRewardTask Performance and AnalysisYoung AdultAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideCentral Nervous System StimulantsMethylphenidatePropylamines

Identifiers

PMID21346736
PMCPMC3079849
OpenAlexW2048513666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.